Galectin Therapeutics Inc. (GALT) Stock Price

GALTStock
$3.995.37%52W
Market Cap$402.39M
P/E
PEG Ratio-36.15
Div yield
Beta0.38

GALT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)26.34%
Price vs S&P 500 (4W)11.40%
PEG Ratio-36.15
VGM Score74.02

GALT Earnings Surprise History

Q2 25-0.12est. -0.16
Q3 25-0.13est. -0.11
Q4 25-0.08est. -0.10
Q1 26-0.08est. -0.06
Q2 26-0.14est. -0.09

GALT Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.14
4.14
4.14
4.14

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
GALTGalectin Therapeutics Inc.
B$3.99
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Galectin Therapeutics Inc.

Galectin Therapeutics is a clinical-stage biopharmaceutical company developing belapectin, a galectin-3 inhibitor targeting liver fibrosis, cancer, and related diseases. Preclinical studies have demonstrated belapectin's potential to reverse liver fibrosis and cirrhosis, addressing significant unmet medical needs.